US Edition
Published • loading... • Updated
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Verdict HospitalReposted by 
Clinical Trials Arena
Clinical Trials ArenaPatient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial
Senti Biosciences has completed enrolment of patients in its Phase I clinical trial assessing SENTI-202 in adults with relapsed or refractory acute myeloid leukaemia (R/R AML).The post Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial appeared first on Hospital Management.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
